Trade RGNX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
REGENXBIO Inc. (RGNX) is trading at US$7.16, up 4.07% today as of Oct 15, 16:00 EDT. The company has a market capitalisation of US$707.66M. Over the past 52 weeks, RGNX has traded between US$5.46 and US$16.19. On Syfe you can trade RGNX with $0 commission and add it to your watchlist.
| Previous close | US$6.88 |
|---|---|
| Market cap | US$707.66M |
| 52-week range | US$5.46 – US$16.19 |
| Volume | 1.19M |
| Exchange | US |
REGENXBIO Inc.
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Year: 2015
Top Premarket Gainers
Aug 28, 11:15 AM · MT Newswires
Sector Update: Healthcare Stocks Softer Late Afternoon
Aug 24, 7:47 PM · MT Newswires
Top Midday Decliners
Aug 24, 6:10 PM · MT Newswires
Sector Update: Healthcare Stocks Decline in Afternoon Trading
Aug 24, 5:50 PM · MT Newswires
REGENXBIO Inc. (RGNX) stock is trading at US$7.16, +4.07% from the previous close of US$6.88.
The market cap for REGENXBIO Inc. (RGNX) stock is approximately US$707.66M.
The 52-week high for REGENXBIO Inc. (RGNX) stock is US$16.19.
The 52-week low for REGENXBIO Inc. (RGNX) stock is US$5.46.
REGENXBIO Inc. (RGNX) does not currently pay a dividend.
Stay on top of RGNX
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
